首页> 外文期刊>Journal of tissue engineering and regenerative medicine >Biomaterials in myocardial tissue engineering
【24h】

Biomaterials in myocardial tissue engineering

机译:心肌组织工程学中的生物材料

获取原文
获取原文并翻译 | 示例
           

摘要

Cardiovascular disease is the leading cause of death in the developed world, and as such there is a pressing need for treatment options. Cardiac tissue engineering emerged from the need to develop alternative sources and methods of replacing tissue damaged by cardiovascular diseases, as the ultimate treatment option for many who suffer from end-stage heart failure is a heart transplant. In this review we focus on biomaterial approaches to augmenting injured or impaired myocardium, with specific emphasis on: the design criteria for these biomaterials; the types of scaffolds - composed of natural or synthetic biomaterials or decellularized extracellular matrix - that have been used to develop cardiac patches and tissue models; methods to vascularize scaffolds and engineered tissue; and finally, injectable biomaterials (hydrogels) designed for endogenous repair, exogenous repair or as bulking agents to maintain ventricular geometry post-infarct. The challenges facing the field and obstacles that must be overcome to develop truly clinically viable cardiac therapies are also discussed. Copyright (c) 2014 John Wiley & Sons, Ltd.
机译:心血管疾病是发达国家的主要死亡原因,因此迫切需要治疗选择。心脏组织工程学的出现是因为需要开发替代来源和方法来替换因心血管疾病而受损的组织,因为对于许多患有晚期心力衰竭的患者而言,最终的治疗选择是心脏移植。在这篇综述中,我们集中于增加受伤或受损心肌的生物材料方法,特别着重于:这些生物材料的设计标准;由天然或合成生物材料或脱细胞的细胞外基质组成的支架的类型,这些支架已用于开发心脏补丁和组织模型;使支架和工程组织血管化的方法;最后,可注射生物材料(水凝胶)设计用于内源性修复,外源性修复或作为填充剂以在梗塞后维持心室的几何形状。还讨论了该领域面临的挑战和开发真正临床可行的心脏疗法必须克服的障碍。版权所有(c)2014 John Wiley&Sons,Ltd.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号